1. Scrip
  2. >>Business

Lupin: Glad To Have Dodged Humira Bullet, Lucentis Biosimilar Closer As Phase III Trials Succeed

Amazon, Mark Cuban Not Upset US Market Dynamics

 
• By Vibha Ravi

Lupin’s CEO highlights market access strategy as a key tool to ensure biosimilars success in the US while being relieved the company didn’t launch a Humira biosimilar. She also mentions Amazon and Mark Cuban have not upset market dynamics for generics in the US and a Lucentis biosimilar is closer to a global launch post Phase III trial success

Growth Strategy
Good Business Strategy Is Vital To Success • Source: Shutterstock

Lupin Limited CEO Vinita Gupta thinks the company dodged a bullet as it kept away from the adalimumab race but is positive that a calibrated strategy for other biosimilars could work.

Answering a question during a call for Q1 FY25 results, on whether she is worried about the future trajectory for planned biosimilars given the fate of rivals who launched a Humira (adalimumab) biosimilar, Gupta said “We are really glad that we didn't have adalimumab, because the number of competitors with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.